new toolkit add depth
launch new risk reward framework us specialti
pharmaceut enhanc data content analyt
across firm add context invest view morgan
stanley roll framework across research global
options-impli probabl price target use proprietari model
option trade desk
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
quant recommend proprietari most/best alpha model
stock exposur key invest theme
also find updat risk reward dynam data interact
access research portal avail
new framework put invest view specialti
pharmaceut coverag context
risk reward theme includ earn qualiti self help secular
bhc benefit improv earn qualiti busi mix
improv anim health stock offer durabl growth respit
washington drug price uncertainti think overweight-r
equal-weight-r well posit durabl growth face
broader healthcar polit uncertainti stock carri rel high
valuat exposur govern price risk us gener
industri sale trend appear improv new product contribut
difficult predict opioid litig gener price-fix develop
wildcard continu believ investor steer clear stock
greatest litig exposur underweight-r teva
see risk propos global opioid settlement final
plan resolut gener price fix investig could posit
potenti penalti immateri
expect bausch health bhc share outperform organ revenu
growth improv mid-singl digit rang driven new product
contribut fade gener pressur stock valuat benefit
busi mix improv bhc pay debt
anticip upward pressur horizon consensu project
specif krystexxa teprotumumab sale think
compani transit rare diseas rheumatolog remain
underappreci expect orphan/rheumatolog segment
total compani revenu rise
expect elanco share outperform investor increasingli
focu bayer transact posit margin expans prospect long
term pipelin potenti see potenti share partial
narrow valuat gap ep
ep execut face competit threat bayer uncertainti
author materi act capac attorney
hold materi intend either legal opinion
legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig ip
prosecut talent trial proceed locat juri composit judg
examin composit investor contact legal advisor issu
law relat subject matter materi
consensu
pt repres revenu lower spec pharma median see
warrant given pipelin uncertainti long-term pressur royalti revenu
rate equal-weight rel
prospect balanc low stock
low expect pipelin
schizophrenia vumer
valuat appear low share
trade atjust revenu
may posit pipelin strateg
view descript risk reward theme
pipelin surpris upsid earn
pipelin surpris upsid earn
expect
expect cancer
data encourag revenu
higher base case due key
optim cost drive better earn
cash ow
pipelin uncertainti persist market
pipelin uncertainti persist market
product perform line
product perform line
expect
uptak modest market product
vivitrol aristada line
surpris downsid incl
surpris downsid incl
disappoint data vivitrol
aristada growth slower anticip
drive total revenue base
clinic trial
franchis sale trend includ vivitrol
financi result rel expect
pipelin newsow particular
china india
view explan region hierarchi
research highest favor quintil
result pipelin surpris potenti
product disappoint cash ow
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
wide risk reward cone reect volatil natur stock
pt base ebitda slight premium current gener peer mean
reect less brand opioid litig risk slightli stronger
ebitda compound-annual-growth-rate vs gener peer teva mean low-singl digit
new manag drive improv
prospect see balanc risk-reward
given high nancial leverag busi
ebitda driven pipelin
contribut cost save
high leverag year-end net
debt divid adj ebitda
nancial strateg
litig continu overhang
amneal brand opioid
exposur like peer
view descript risk reward theme
ebitda
result forecast fda approv major
result forecast fda approv major
new gener candid yield
new gener candid yield
upsid amneal beat expect
new product margin ebitda
project futur accret
ebitda
driven new launch note
driven new launch note
compound-annual-growth-rate revenue
ebitda driven pipelin contribut
cost constraint time new
product launch imposs predict
forecast subject chang
ev/ebitda
busi deterior new
busi deterior new
launch delay amneal face
launch delay amneal face
litig problem buy group
opportun delay ebitda
project neg litig
newsow hurt stock
adj ebitda excl sbc expens
gcopaxon expect approv launch
bneupogen expect approv launch
financi result rel expect
updat gener price xing opioid
extern busi develop transact
china india
view explan region hierarchi
upsid risk improv gener price
environ result expect posit
resolut price xing opioid litig
value-enhanc activ
downsid risk result expect
pressur cash ow issu problemat legal
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt base ev/ ebitda discount specialti pharma peer
expect share tooutperform
organ revenu growth improv
mid-singl digit rang driven new
product contribut fade gener
busi mix improv bausch
drive higher sale new product
gradual debt paydown improv
debt/ebitda metric come year
bhc wide bull-to-bear skew given
high leverag small chang ev
enterpris valu drive larg chang
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
bull case ebitda
result surpris upsid
result surpris upsid
manag turn busi around
manag turn busi around
sale expect driven new
product launch lead ebitda upsid
investor enthusiasm
busi mix nancial leverag
prospect grow boost multipl
base case ebitda
new product launch fade loe
new product launch fade loe
posit busi mix shift toward
higher-valu franchis vision care
expect new product launch
contribut growth loss exclus
impact dissip come year
bear case ebitda
manag struggl execut
manag struggl execut
product launch ramp mediocr
newsow concern
updat relat potenti gxifaxan threat
bhc led lawsuit vs sandoz alleg patent infring
quarterli nancial result guidanc updat
xifaxan sale momentum competit
de-lever progress balanc sheet
china india
view explan region hierarchi
result expect
multipl step due improv busi
strateg action enhanc prospect reduc
nancial leverag boost share
busi execut disappoint bausch
guid consensu
certain hedg fund exposur held mspb
inform may inconsist may reect
exposur short exposur sector total net
short exposur across sector long exposur
pt base pro forma ep discount ep project
pro forma ep compound-annual-growth-rate vs
pro forma bull case ep
result forecast due new product
result forecast due new product
strength delay competit entrant
strength delay competit entrant
faster margin expans revenu upsid
driven key franchis strength new
pipelin contribut competit
bayer transact synergi realiz
faster expect ep
pro forma base case ep
revenu growth signicantli
revenu growth signicantli
pro-forma incl bayer ah revenu growth
oper margin expand
stand-alone pro
forma believ management
deliv margin expans target
driven improv cost save initi
improv busi mix expect
pipelin bear fruit medium-long
overweight see
revenue ep plu attract
plan acquisit bayer ah
acceler margin expans
expans ebitda
expans
see potenti margin upsid
cost save earlier/larg
pipelin progress drive
greater investor enthusiasm medium-
view descript risk reward theme
pro forma bear case ep
shortfal bayer deal disappoint global
shortfal bayer deal disappoint global
entrant enter broad-spectrum
trio companion anim second
weak drive demand downsid ep
equiti issuanc depend anti-trust discuss
fda expect complet review end
bayer ah full-year result
competitor simparica trio surprisingli
approv fda march brand
rumensin perform well face new us
result compet pressur hurt sale
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
financi result rel expect
global livestock companion anim
china india
view explan region hierarchi
research highest favor quintil
wide risk reward cone reect volatil natur stock
pt base ebitda target multipl gener peer averag
given project long-term ebitda declin high leverag litig risk
bull case ebitda
gener brand exceed
gener brand exceed
expect cellulit product
expect cellulit product
success anticip opioid litig
success anticip opioid litig
newsow surprisingli encourag
newsow surprisingli encourag
endp gener xiaex brand sale
expect drive ebitda
expect cch cellulit
success differenti price vs
newsow encourag small
expans ev drive larg equiti upsid
base case ebitda
valuat appear low project long-
valuat appear low project long-
term result consensu
term result consensu
concern litig risk assum
concern litig risk assum
cellulit disappoint opioid litig
exposur yield greater litig risk
gener pure-play fda approv cch
cellulit commerci success
constrain questionableefcaci
valuat appear low project
long-term result consensu see
durabl key franchis
adrenalin vasostrict difcult
ebitda
high leverag year-end net
debt divid adj ebitda
nancial strateg
yield greater litig risk certain
stock
consensu
view descript risk reward theme
bear case ebitda
financi result forecast hh
financi result forecast hh
allow separ price cellulit
allow separ price cellulit
sale squeez competit
pressur deterior price
ebitda expect hh
notallow separ lower price
rel xiaex multipl contract
gener busi perform competit
opioid litig price xing newsow
hh price decis action cch cellulit
month fda approv
view explan region hierarchi
base gx busi deliv higher
durabl earn anticip cch
cellulit newsow better expect incl
hh grant separ price xiaex
competit threat hh assign
separ price cch cellulit neg
opioid litig price xing develop
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
ebitda appli multipl premium mean higher
valu rheumatology/orphan drug franchis grown repres prot key
driver krystexxa grow strongli expect solid teprotumumab launch rise
overweight share base
upon compani transit
orphan/rheumatolog expect
compani valuat expand
segment earn rise
estim
teprotumumab compel new drug
gener us sale
primari uncertainti includ risk
polit scrutini futur pbm pressur
remain overhang alreadi model
franchis step signicantli
next year
view descript risk reward theme
bull case ebitda
krystexxa tepro sale higher
krystexxa tepro sale higher
model enhanc prospect
model enhanc prospect
sale uptak stronger anticip
revenue forecast ebitda
drive multipl expans
base case ebitda
upward pressur long-term sale
upward pressur long-term sale
prospect mix shift toward
prospect mix shift toward
posit orphan/rheum growth
continu grow strongli
addit transact enhanc
bear case ebitda
threat emerg investor react
threat emerg investor react
neg
neg krystexxa sale fall
primari miss due commerci
pbm pressur revenue
forecast ebitda
competit threat key franchis caus
quarterli result guidanc updat
krystexxa salesperform futur studi
view explan region hierarchi
research highest favor quintil
earn result nancial guidanc
earn result guidanc updat
teprotumumab sale uptak bigger/fast
expect primari declin less
anticip pipelin option emerg
downsid competit threat key
franchis emerg investor react neg
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt base base case ep earn highli
concentr singl franchis xyrem total compani sale face
patent cliff
prospect balanc longer term
revenu ebitda ep
signic relianc xyrem franchis
total co sale expect
next-gen fail retain
major xyrem sale gener fulli
enter market
 could enhanc prospect
diversifi away xyrem franchis
initi impact share difcult
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
bull case ep
sales/ep forecast pipelin
sales/ep forecast pipelin
signic valu xyrem sunosi sale
exceed estim drive ep
project pipelin progress drive
upsid long-termgrowth enhanc
current xyrem concentr
base case ep
term see price-to-earnings multipl
term see price-to-earnings multipl
constrain due xyrem-rel
constrain due xyrem-rel
uncertainti project ep compound-annual-growth-rate
high singl digit gener threat
xyrem repres signic
match xyrem benet-risk
view descript risk reward theme
bear case ep
threat hurt multipl hurt
threat hurt multipl hurt
share key franchisesal
forecastand invest spend higher
anticip drive ep
surprisingli deliv equival benet-
risk ratio twice-nightli xyrem investor
react neg multipl trade
low seen select large-cap biotech
 xyrem sale trends/outlook low-sodium
newsow potenti xyrem competitor
view explan region hierarchi
research highest favor quintil
upsid risk result expect
xyrem transit strategi low sodium
value-enhanc activ
downsid risk result expect
threat rise transact disappoint
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
sunosi ex-u launch anticip eu approv earli
approv launch ramp includ convers
strategi updat expect redeem prv
pt base upon stand-alon ebitda estim ev
stand-alon ebitda net debt yield equiti valu
share price base share valuat low end
delwar corpor govern low
believ difcult predict
organ sale earn prospect beyond
given gener eros risk limit
invest spend percentag
yr revenue ep
forecast continu lower
nancial leverag rule
risk price xing litig cash
view opioid litig minor
risk brand
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
ebitda expect corpor
ebitda expect corpor
launch improv price trend drive
revenu upsid efcienc add
ebitda drive ebitda
project ev/ebitda expand
improv result reduct nancial
leverag initi dividend govern
chang us price xing litig
ev/bas case ebitda
plan corpor action posit
plan corpor action posit
out-year earn
out-year earn
consensu plan reduc debt
leverag initi dividend chang
incorpor delawar posit
view rel consensu
project lower gross margin due
competit issu higher spend
predict outcom price xing
investig potenti penalti could
balanc overhang remov
view descript risk reward theme
ev/bear case ev/ebitda
shortfal occur neg
shortfal occur neg
short expect invest
spend rise drive ebitda
success new product launch
china india
view explan region hierarchi
research highest favor quintil
result forecast corpor action
benet multipl expect
price xing overhang lift
result could fall short
investig may result ne busi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
newco nancial guidanc deal close
segment perform better expect
gener proair drive ep
receiv favor outcom irish
tax disput stock re-rat higher
deliv result slightli
deliv result slightli
expect nancial uncertainti
expect nancial uncertainti
ep annual next three
year manag execut well
improv consum busi execut
rx busi tax disput uncertainti
pt base ep target price-to-earnings discount mean
lower end standard deviat rang con ntm ep
reect potenti tax liabil model
new manag drive consum
busi improv balanc
rx busi tax disput
project modest revenu
earn growth come year
ep
await clariti rx busi
resolut exit plan
consum growth driver upsid
view descript risk reward theme
busi perform disappoint rx exit
busi perform disappoint rx exit
value-destruct tax disput newsow
tax disput newsow
concern
concern consum busi growth
disappoint due competit pressur rx
struggl due price pressur lack
new launch ep
result penalti rx exit hurt
sharehold valuat due dis-synergi
low valuat face neg tax
quarterli result guidanc updat
gproair fda approv launch
view explan region hierarchi
research highest favor quintil
rx exit action crystal valuat gener
gproair potenti fda approv launch
tax liabil updat high court hear judici review
proceed apr irish tax liabil
quarterli result guidanc updat
dilut associ rx exit better
posit newsow tax disput
new product launch delay
tax disput newsow neg
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt base calendar year ep target price-to-earnings toward
middl phibro long term one standard deviat price-to-earnings rang
see potenti improv growth
prospect believ share reect
expect turnaround begin
grow global popul
increas afuenc drive steadi
global demand anim protein
consumpt limit natur resourc
produc product pressur continu
drive need anim health diseas
compani oper nich anim
health mineral/chem market
limit industri sourc product
trend make difcult forecast
view descript risk reward theme
ep
growth higher expect phibro
growth higher expect phibro
particip industri consolid
particip industri consolid sale
upsid nutritionals/vaccin
emerg market drive ep
forecast phibro particip industri
ep
growth led nutrit vaccin
growth led nutrit vaccin
estim anim health segment
grow includ increas
nutrit specialti increas
vaccin off-set declin mfa
project mid high singl digit ep growth
next two year compound-annual-growth-rate
ep
sale shortfal caus downsid nancial
sale shortfal caus downsid nancial
outlook stock multipl
outlook stock multipl competit
pressur econom disrupt caus
vaccin growth disappoint
franchis outsid china declin ep
project price-to-earnings multipl
contract weaker result
mfa growth
macro trend drive livestock industri
global demand protein consumpt
quarterli nancial result rel
product launch penetr higher-
china india
view explan region hierarchi
upsid risk includ result expect
faster uptak new product posit pipelin
develop value-enhanc
regulatori action key antibiot
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
pt base ev/ebitda discount gener peer averag
project ebitda compound-annual-growth-rate
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
manag execut well busi
turnaround effort see risk
propos global opioid settlement
naliz plan
could upward pressur near-
term ep due addit cost cut
lack new gener copaxon entrant
high leverag ebitda
nancial strateg constraint
yield greater litig risk
consensu
view descript risk reward theme
bull case ebitda
result expect litig
overhang resolv ebitda higher
base case due gener sale upsid
new cost cut initi andlack fda
approv new gener copaxon
settlement naliz plan
gener price xing inquiri resolv
immateri penalti multipl step
base ebitda
wear underweightdu litig risk
wear underweightdu litig risk
addit cost cut drive earn
higher limit visibl longer
share fear may
naliz plan price xing
investig could also result penalti
bear ebitda
earn disappoint due competit
earn disappoint due competit
pressur unfavor resolut
pressur unfavor resolut
on-going litig ebitda lower
base case due gener shortfal fda
approv addit gener copaxon
settlement naliz litig risk
mount gener price xing investig
result concern penalti financi
leverag increas price-to-earnings declin
north america canada
ow progress nancial leverag
china india
view explan region hierarchi
research highest favor quintil
propos global opioid settlement naliz
ow forecast
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
base case ep target multipl high end histor
zoeti combin compel
convers balanc rel high stock
ep growth
develop tuck-in apotenti
pressur new product disappoint
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
jan gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
bull case ep
growth project zoeti pursu
growth project zoeti pursu
plu upsid yield ep
forecast tuck-in could
enhanc prospect
base case ep
driven growth key companion anim
driven growth key companion anim
product project compound-annual-growth-rate revenu
growth ep compound-annual-growth-rate
annual global roll-out new
product give us condenc
bear case ep
face lower end-market growth greater
face lower end-market growth greater
nancial result fda surprisingli
approv simparica trio march
approv without puppi claim zoeti
face new competitor key companion
price-to-earnings multipl contract
expect complet review end launch
simparica trio us launch exp earli eu canada
quarterli result guidanc updat
zoeti becom activ deploy capit
acquir products/compani
competitor could launch product
compet directli key zoeti growth driver
china india
view explan region hierarchi
research highest favor quintil
upsid quarterli result guidanc
margin expans expect
competitor perform wors anticip
new product approv delay launch
competit threat key product emerg
environment econom issu drivezoeti
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
 co llc act financi advis abbvi inc
relat propos offer acquir allergan plc allergan announc
june propos transact effect mean scheme
arrang chapter part compani act subject
approv allergan sharehold regulatori approv customari close
condit report inform provid herein intend provid
vote advic ii serv endors propos transact iii result
procur withhold revoc proxi action secur holder
agre pay fee financi servic includ
transact fee conting upon consumm transact pleas
refer note end report
